权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting the cytokine circuitry of KRAS-driven lung cancer

靶向 KRAS 驱动肺癌的细胞因子回路

基本信息

批准号：
9042321
负责人：
David A Barbie
金额：
$ 39.46万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2020-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9042321
关键词：
Alleles Autophagocytosis Basic Science Biological Markers Biology Biopsy Cancer Etiology Cancer Model Cancer Patient Cancer cell line Cell Proliferation Cell Survival Cessation of life Clinical Clinical Trials Colorectal Cancer Combined Modality Therapy Data Development Disease Feedback Genetic Genetic Crosses Genetic Determinism Genetically Engineered Mouse Genotype Goals Grant Health Homologous Gene Human Immune In Vitro Inflammation Interleukin-6 Investigation JAK1 gene Janus kinase KRAS2 gene Laboratories Lead Learning MEK inhibition MEKs Malignant Neoplasms Malignant neoplasm of lung Mediator of activation protein Molecular Mus Mutate Mutation Non-Small-Cell Lung Carcinoma Oncogenes Oncogenic Pancreatic Ductal Adenocarcinoma Pathway interactions Patients Pharmaceutical Preparations Pharmacodynamics Pharmacogenetics Phase Phosphotransferases Production Proto-Oncogene Proteins c-akt Public Health RANTES Research Research Project Grants Resistance Role Serum Signal Pathway Signal Transduction Staging Subgroup TBK1 gene TP53 gene Time Toxic effect Translational Research United States Work autocrine base bench to bedside cancer cell cell motility cell transformation chemotherapeutic agent cytokine disorder control docetaxel drug development in vivo inhibitor/antagonist insight kinase inhibitor metaplastic cell transformation migration mortality mouse model mutant neoplastic cell novel novel therapeutics pre-clinical research clinical testing research study resistance mechanism response targeted treatment therapeutic target therapy resistant tumor tumorigenic

项目摘要

DESCRIPTION (provided by applicant): The goal of this research project proposal is to investigate a novel combination therapy for KRAS-driven non-small cell lung cancer (NSCLC) that involves inhibition of pro-tumorigenic cytokine production. Work from this laboratory identified the JAK kinase inhibitor CYT387 (momelotinib) as a potent inhibitor of the immune signaling kinases TBK1/IKK?, disrupting a cytokine circuit that oncogenic RAS engages to promote tumor cell survival and migration. Although efficacious as single agent therapy in Kras-driven murine lung cancer, combination pathway inhibition with a MEK inhibitor resulted in synergy and prolonged tumor regression in an aggressive mouse model of Kras-p53 driven lung cancer. The broad, long term objective is to perform research at the bench to bedside interface to explore further the mechanistic basis that underlies the synergy of this combination therapy, and to identify additional strategies to enhance response and overcome resistance. A unique aspect of this proposal is that it spans basic and translational research and incorporates analysis of an actual clinical trial impacting patients. Specific aims are to: 1) Explore synergy and resistance to TBK1 and MEK inhibition in murine Kras-driven lung cancer through further genetic and pharmacologic studies. 2) Elucidate the molecular circuitry responsible for TBK1/MEK inhibitor synergy, and 3) Evaluate response and resistance to momelotinib/trametinib combination therapy in a phase 1b/2 clinical trial in human KRAS mutant NSCLC. The use of mouse lung cancer models will facilitate pharmacogenetic and pharmacodynamics studies that will define the specific activities of the momelotinib/trametinib combination. Genetic crosses of conditional TBK1 null or kinase dead mice into the oncogenic Kras-driven lung cancer model, together with selective JAK and MEK inhibitor treatment, will identify the unique role of TBK1 in regulating this autocrine cytokine circuit in vivo. Analysis of momelotinib/trametinib efficacy across Kras, Kras-p53, and Kras-Lkb1 murine lung cancer models will determine genetic modifiers of response and de novo resistance. Further investigation of TBK1 signaling in KRAS-dependent human cancer cell lines in vitro will elucidate the mechanism by which its inhibition leads to feedback activation of MEK-ERK signaling, yielding important biologic insights and a better understanding of TBK1/MEK inhibitor synergy. Finally, the determination of resistance mechanisms that develop in mouse models and in patients will further define the key activities of these inhibitors. Through these complementary studies, the ultimate goal is not only to understand mechanism and target this therapy to the appropriate subgroup of patients, but also to identify additional strategies for combination therapy that leads to durable control of this aggressive disease.

描述（由申请人提供）：本研究项目提案的目标是研究一种新型联合治疗KRAS驱动的非小细胞肺癌（NSCLC），包括抑制促肿瘤细胞因子的产生。该实验室的工作确定JAK激酶抑制剂CYT 387（momelotinib）是免疫信号激酶TBK 1/IKK？的强效抑制剂，破坏致癌RAS参与促进肿瘤细胞存活和迁移的细胞因子回路。尽管在Kras-p53驱动的小鼠肺癌中作为单一药剂疗法是有效的，但在Kras-p53驱动的肺癌的侵袭性小鼠模型中，与MEK抑制剂的组合途径抑制导致协同作用和延长的肿瘤消退。广泛的长期目标是在实验室到床边界面进行研究，以进一步探索这种联合治疗协同作用的机制基础，并确定其他策略以增强反应和克服耐药性。该提案的一个独特之处在于，它涵盖了基础和转化研究，并结合了对影响患者的实际临床试验的分析。具体目标是：1）通过进一步的遗传学和药理学研究，探索在鼠Kras驱动的肺癌中对TBK 1和MEK抑制的协同作用和抗性。2)阐明负责TBK 1/MEK抑制剂协同作用的分子回路，和3）在人类KRAS突变型NSCLC的1b/2期临床试验中评价对momelotinib/曲美替尼联合治疗的应答和耐药性。使用小鼠肺癌模型将促进药物遗传学和药效学研究，这些研究将确定momelotinib/曲美替尼组合的特定活性。将条件性TBK 1缺失或激酶死亡小鼠与致癌Kras驱动的肺癌模型进行遗传杂交，以及选择性JAK和MEK抑制剂治疗，将确定TBK 1在体内调节这种自分泌细胞因子回路中的独特作用。分析 momelotinib/trametinib在Kras、Kras-p53和Kras-Lkb 1小鼠肺癌模型中的疗效将决定应答和从头耐药的遗传修饰剂。进一步研究TBK 1信号在体外KRAS依赖性人类癌细胞系中的作用，将阐明其抑制导致MEK-ERK信号反馈激活的机制，产生重要的生物学见解，并更好地理解TBK 1/MEK抑制剂协同作用。最后，确定在小鼠模型和患者中产生的耐药机制将进一步确定这些抑制剂的关键活性。通过这些补充研究，最终目标不仅是了解机制并将这种疗法靶向适当的患者亚组，而且还确定了联合治疗的其他策略，从而持久控制这种侵袭性疾病。